Review Article

Progenitor Cell Therapy for the Treatment of Central Nervous System Injury: A Review of the State of Current Clinical Trials

Table 1

Listing of location and details of current clinical trials being completed to investigate the potential role of bone marrow-derived progenitor cell therapeutics for the treatment of ischemic stroke.

Location of StudyStudy DesignDeliver RouteSample SizeCell TypeInclusion CriteriaOutcomesTime Window

United States
(The University of Texas in Houston)
Single armIV10Autologous BMMCs- MCA stroke
- 18–80 yo
- NIHSS 6 to 20
Safety and feasibility24 to 72 hrs

Taiwan
(The China Medical University Hospital)
Randomized (cell infusion versus conventional treatment)IC30Autologous peripheral blood CD34+ cells- Stable deficits hemiplegia
- 35–70 yo
- NIHSS 9 to 20
Safety and efficacy6 months to 5 years

Spain
(Hospital Universitario Central de Asturias)
Single armIA20Autologous CD34+ bone marrow cells- MCA stroke
- 18–80 yo
- NIHSS ≥ 8
Safety5 to 9 days

France
(University Hospital of Grenoble)
Randomized (Control versus 2 treatment groups)IV30Autologous bone marrow derived progenitor cells- Carotid territory stroke
- 18–65 yo
- NIHSS > 2
Feasibility and tolerability6 weeks

United Kingdom (Imperial College London)Single armIA10Autologous CD34+ bone marrow cells- MCA stroke
- 30–80 yo
- Severe stroke conforming to the TACS phenotype (weakness, homonymous hemianopia and a focal cognitive deficit
Safety and tolerability7 days

Brazil
(Federal University of Rio de Janeiro)
2 arms (non randomized: 10 IA/5IV)IV/IA15Autologous BMMCs- MCA stroke
- 18–75 yo
- NIHSS 4 to 20
Safety3 hrs to 90 days

IV: intravenous; IA: intra-arterial; IC: intracerebral; BMMC: bone marrow mononuclear cells; MCA: middle cerebral artery; NIHSS: National Institutes of Health Stroke Scale; TACS: total anterior circulation stroke.